Privium Fund Management B.V. Invests $2.58 Million in Abivax SA Sponsored ADR $ABVX

Privium Fund Management B.V. bought a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, Holdings Channel.com reports. The firm bought 30,412 shares of the company’s stock, valued at approximately $2,582,000. Abivax accounts for about 0.5% of Privium Fund Management B.V.’s portfolio, making the stock its 26th largest holding.

Other institutional investors also recently modified their holdings of the company. First Horizon Corp bought a new position in Abivax in the 3rd quarter worth $36,000. Covestor Ltd purchased a new stake in Abivax in the third quarter worth about $96,000. Bank of America Corp DE grew its stake in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares during the last quarter. HighVista Strategies LLC grew its stake in shares of Abivax by 4.3% in the second quarter. HighVista Strategies LLC now owns 51,156 shares of the company’s stock worth $391,000 after acquiring an additional 2,092 shares during the last quarter. Finally, Moody Aldrich Partners LLC purchased a new stake in Abivax during the 3rd quarter valued at about $207,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $111.15 on Friday. The company has a market capitalization of $8.72 billion, a price-to-earnings ratio of -26.59 and a beta of 0.68. The firm’s 50-day moving average is $123.33 and its 200 day moving average is $96.08. Abivax SA Sponsored ADR has a 12 month low of $4.77 and a 12 month high of $148.83. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. Research analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ABVX shares. Morgan Stanley upped their price target on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Barclays began coverage on shares of Abivax in a report on Monday, October 13th. They set an “overweight” rating and a $142.00 target price for the company. Wolfe Research upgraded Abivax to a “strong-buy” rating in a research report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Finally, BTIG Research boosted their price objective on Abivax from $120.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Abivax currently has an average rating of “Moderate Buy” and a consensus price target of $135.08.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.